PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Redox Rep. Author manuscript; available in PMC 2011 January 1.
Published in final edited form as:
PMCID: PMC2956440
NIHMSID: NIHMS238740

Indoleamine 2,3-dioxygenase and 3OH-kynurenine Modifications are found in the Neuropathology of Alzheimer Disease

Abstract

Tryptophan metabolism, through the kynurenine pathway (KP), produces neurotoxic intermediates that are implicated in the pathogenesis of Alzheimer disease (AD). In particular, oxidative stress via 3-hydroxykynurenine (3-HK) and its cleaved product 3-hydroxyanthranilic acid (3-HAA) significantly damages neuronal tissue and may potentially contribute to a cycle of neurodegeneration through consequent amyloid-β accumulation, glial activation, and upregulation of the KP. To determine the role of the KP in eliciting and continuing oxidative stress within AD brain, we used immunocytochemical methods to show elevated levels of 3-HK modifications and the upstream, rate-limiting enzyme indoleamine 2,3-dioxygenase (IDO-1) in AD brain when compared to controls. Importantly, the association of IDO-1 with senile plaques was confirmed, and for the first time, IDO-1 was shown to be specifically localized in conjunction with neurofibrillary tangles. As senile plaques and neurofibrillary tangles are the pathological hallmarks of AD, our study provides further evidence that the KP is involved with the destructive neurodegenerative pathway of AD.

Keywords: Alzheimer disease, amyloid-β, hyperphosphorylated tau, indoleamine 2,3-dioxygenase, kynurenine, kynurenine pathway, quinolinic acid, tryptophan

Introduction

The kynurenine pathway (KP) is the primary mode of L-tryptophan catabolism in mammalian tissues1, responsible for 95% of L-tryptophan degradation2 (Figure 1). Though chiefly carried out to yield the ubiquitous coenzymes nicotine adenine dinucleotide (NAD+) and nicotine adenine dinucleotide phosphate (NADP) for use in basic cellular processes3, the KP plays additional roles in cellular, particularly neuronal, physiology4-6. Notably, L-tryptophan is an essential amino acid, and thus must be retrieved in the diet7. Its balanced catabolism is therefore important for the survival of a given tissue: upregulation of the KP depletes the surrounding cells of L-tryptophan, while the opposite reduces cellular levels of NAD+ and NADP. Accordingly, the KP is utilized in a pathophysiological response to invading microorganisms; a depletion of L-tryptophan via the KP has antimicrobial, antiviral, and antiproliferative activities due to the basic cellular need for dietary tryptophan7-9. However, as some intermediates of the KP have neurotoxic effects, an upregulation of the pathway also threatens the surrounding tissue10, 11. Specifically, the L-tryptophan metabolites 3-hydroxykynurenine (3-HK) and 3-hydroxyanthranilic acid (3-HAA) are associated with the generation of the potent oxidative species superoxide (O2-), hydroxyl radical (H·) and hydrogen peroxide (H2O2), which frequently contribute to macromolecular damage within defective cells12-15. Moreover, quinolinic acid (QUIN), a downstream metabolite of 3-HAA, is also a potent neurotoxic element16, 17 that has been shown to exhibit excitotoxic effects via N-methyl D-aspartate (NMDA) receptor agonism, as well as oxidative stress via lipid peroxidation18-22. Consequently, any unbalanced upregulation of the KP is likely to elicit some degree of detriment to surrounding tissue, and this phenomenon is manifest in several inflammatory-associated diseases, such as multiple sclerosis23, AIDS-dementia complex24, and cerebral malaria25-27, as well as in Alzheimer disease (AD)28, 29.

Figure 1
The Kynurenine Pathway.

AD is a complex neurodegenerative disease that is characterized by hippocampal neuronal loss and severe dementia in its later stages30. The pathological mechanisms that underlie the disease are a subject of moderate controversy, however it is known that oxidative stress and neuroinflammation play pivotal roles31. The mediators of neuroinflammation in AD are microglia and astrocytes32, 33, known sites of KP catabolism which contain all enzymes required for KP progression34-36. A recent study also implicated QUIN, the downstream component of the KP, with tau phosphorylation in AD through reduction of tau phosphatases PP2A, PP1, and PP537. Tau hyperphosphorylation, resulting in neurofibrillary tangle (NFT) formation, represents a hallmark feature of AD that induces severe neuronal detriment upon increasing deposition38. Consequently, AD pathophysiology is believed to involve an upregulation of the KP.

Specifically, serum studies measuring the ratio of 3-HK to L-tryptophan levels found an increased ratio (i.e., more 3-HK) in the serum of AD patients, compared to age-matched and younger controls28. Immunohistochemical studies of AD hippocampal sections similarly demonstrated elevated levels of the upstream, rate-limiting enzyme indoleamine 2,3-dioxygenase (IDO-1) and QUIN in microglia, astrocytes, and neurons, as compared to control subjects, with microglia and astrocytes showing the highest levels29. In this report, we analyzed the relative levels of 3-HK modified proteins in AD hippocampal tissue sections compared to age-matched controls, as well as the levels and localization of IDO-1 in order to discern the role of the KP in AD. Importantly, these results may open new insights into AD therapeutics, particularly via a modification of the catabolism of L-tryptophan.

Materials and Methods

Using Case Western Reserve University IRB approved protocols, brain samples were collected at the time of autopsy. Hippocampal sections from cases of pathologically confirmed AD (n= 12; age 69-96 yr, mean 84 ± 8.2 yr) and from young (n= 3; age 31-54 yr, mean 42 ± 11.5 yr) and age-matched (n= 7; age 66-86 yr, mean 71.5 ± 6.8 yr) controls were collected, fixed in methacarn (methanol: chloroform: acetic acid; 6:3:1), and embedded in paraffin. Sections (6 μm) were cut and processed for immunohistochemistry using the peroxidase-anti-peroxidase method39. Briefly, sections were deparaffinized in xylene, rehydrated in a series of graded ethanol, and endogenous peroxidase activity was removed by incubating 30 min in 3% H2O2. Following a 10-min incubation in 10% normal goat serum, the primary antibodies were applied for 16 h at 4°C. Following successive incubations in secondary antibody and peroxidase-anti-peroxidase complex, staining was developed using 3,3-diaminobenzidine as cosubstrate.

For some cases, the tissue was treated with 50% hydrofluoric acid before pre-embedding (Dako Cytomation, Carpinteria, CA, USA). Antibodies used include; monoclonal anti-IDO-1 (Chemicon, Temecula, CA, USA), anti 3-HK modified Nα-acetyl lysine, Nα-acetyl histidine, Nα-acetyl arginine, and Nα-acetyl cysteine14, anti-phosphorylated tau (Biosource, Carlsbad, CA, USA). As a negative control, the above method was repeated omitting the primary antibody.

Computer-assisted digital analysis was used to measure the level of immunoreaction in pyramidal neurons in three fields from the CA1/2 region of the hippocampus in the AD and control sections. Using a Zeiss axiocam and associated Axiovision software, pyramidal neurons were detected and the intensity of immunoreaction, with the background level of the surrounding neuropil subtracted, was determined for each case. An average neuronal staining level was determined for each case and the Student's t-test was used to statistically compare the different groups.

Western immunoblotting was carried out as previously described40. In brief, brain sections from AD (n = 7; age 65-89 yr) and control (n = 6; age 62-89 yr) cases were homogenized in 10 volume of lysis buffer [50 mM Tris-HCl (pH 7.6), 0.02% sodium azide, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 mg/mL aprotinin, 2 mg/mL antipain, and 1 mM sodium orthovanadate], and centrifuged at 11745 g for 10 min at 4°C. Protein concentrations of each sample's supernatant were assessed by bicinchoninic acid assay (Pierce, Rockford, IL, USA). Separation of proteins was completed by SDS-polyacrylamide gel electrophoresis (20 μg/lane), and subsequently, proteins were electroblotted onto polyvinylidene difluoride membrane as previously described41. Transferred blots were incubated in sequence with blocking agent (10% nonfat milk in Tris-buffered saline solution with Tween 20), mouse monoclonal antibody to 3-HK modifications, and affinity purified goat anti-mouse immunoglobulin peroxidase conjugate was preabsorbed to eliminate human cross-reactivity. Development of blots was completed by using enhanced chemiluminescence reagents (Santa Cruz Biotechnology, Santa Cruz, CA, USA) according to the manufacturer's instructions. Blots were then stripped, as previously published42, and incubated with monoclonal antibody to the constitutively expressed actin protein. Densitometric analysis was performed on the scanned images using Quantity 1 software (Biorad) to determine precise relative protein levels of 3-HK modifications and actin. For each individual case, the 3-HK modification level was divided by the actin level to control for gel loading and allow for more accurate comparative analysis.

Results

IDO-1 was detected in both control and AD tissue as previously described29. Intense labeling of neuronal (Figure 2A) and glial (Figure 2B) accumulations were detected in all cases of AD. Following treatment with hydrofluoric acid, intense labeling of neurofibrillary pathology was seen (Figure 2C). In confirmation that the IDO staining pattern observed indeed represented NFTs, adjacent tissue sections were stained with anti-tau antibody and a replicate staining pattern was observed (data not shown). Additionally, amyloid deposits (Figure 2D) including those with an intense core (Figure 2D, inset), were readily detected.

Figure 2
IDO-1 was detected in both control and AD tissue as previously described. Intense labeling of neuronal (A) and glial (B, arrows) accumulation was detected in all cases of AD. Following treatment with hydrofluoric acid, intense labeling of neurofibrillary ...

3-HK modifications are increased in hippocampal pyramidal neurons in cases of AD compared to controls (Figure 3). In AD, the cytoplasm in neurons extending throughout the entorhinal cortex showed much stronger immunoreactivity (Figure 3B) than age-matched controls (Figure 3A). Quantification of the neuronal levels of 3-HK modifications in the CA1 and CA2 regions of the hippocampus, revealed that the AD cases displayed significantly greater staining intensity than age-matched controls upon quantification (p<0.02) (Figure 3C), as well as controls under age 55 (data not shown). Further data analysis showed there is no significant correlation between the neuronal levels of 3-HK modifications with age in either the AD or control groups.

Figure 3
3-HK modifications are increased in pyramidal neurons in the hippocampus in cases of AD compared to controls. In AD, the cytoplasm in neurons extending throughout the entorhinal cortex shows much stronger immunoreactivity (B) than aged controls (A). C) ...

Western blot data demonstrated 3-HK modifications to be slightly elevated in AD hippocampal tissues, compared to controls (Figure 4A); however, statistical significance was not reached (Figure 4B). Of note, three cases with dual diagnosis of AD and diffuse Lewy body disease (DLBD) demonstrated relatively lower levels of 3-HK compared to AD cases, and, upon their removal from set of AD cases in the comparison between AD and control, the difference in 3-HK concentration between AD and controls reached statistical significance (p=0.0425) (Figure 4B).

Figure 4
A) Western blot showing probes for 3-HK modifications (top) and actin (bottom). B) Quantification of 3-HK modification western blot band intensity. Actin band intensity was used to normalize 3-HK modifications (see methods). When quantification is repeated ...

Discussion

The elevated expression of both 3-HK modifications and IDO-1 in AD tissue sections confirms the upregulation of the kynurenine pathway in AD. As IDO-1 facilitates the rate-limiting step in the catabolism of L-tryptophan, its increased presence strongly indicates the corresponding progression of the KP and its corresponding over-activation of the downstream intermediates 3-HK, ANA, KYNA, and QUIN (the latter three were not monitored in this study). In addition, the co-localization of IDO-1 with AD tauopathies in this study implicates the KP in NFT formation in the brain. Taken together, we believe that amyloid-β (Aβ), through its activation of microglia and astrocytes (discussed below), induces the upregulation of the toxic intermediates of the KP that produce further oxidative stress, excitotoxicity, and tau phosphorylation. Therefore, a potential therapeutic window is identified by the results of our research.

While exact role of Aβ in the pathogenesis of AD is a subject of controversy, accumulating evidence suggests it to be a secondary factor in disease, rather than a primary one31. That is, while Aβ was long regarded to be the primary, causal factor in the development and progression of AD-type dementia, it actually may accumulate as a compensatory response to age-induced increases in oxidative stress31, 43-45. The role of Aβ peptide is therefore initially one of neuronal protection. Briefly, in AD cases with the most extensive deposition of Aβ, as well as those containing NFTs, there are relatively low levels of the oxidative stress marker 8-hydroxyguanosine (8OHG), despite the apparent history of oxidative damage (i.e., advanced glycation endproducts or lipid peroxidation)46. Moreover, Aβ itself demonstrates strong antioxidant properties under appropriate cellular conditions: the peptide contains strong chelating properties for zinc, iron, and copper (highly active oxidative agents)47, 48. However, despite the initial benefits of Aβ secretion, the peptide's eventual extracellular aggregation into senile plaques (resulting from oxidative stress-inducing dityrosine cross-linkages49 and the corresponding insolubility of Aβ) stimulates inflammation that ultimately yields further oxidative stress. It is this latter phenomenon that we believe to be mediated through an upregulation of the KP.

Aβ plaques are known to activate microglial and astrocytic cells in the brain following accumulation and aggregation, and consequent neurotoxic effects. That is, reactive oxygen species production probably occurs as a result of astrocyte and microglia activation50, 51. For instance, the KP is primarily functional in microglia and astrocytes (as well as in infiltrating macrophages). Moreover, all of the enzymes that facilitate the catabolism of L-tryptophan via the KP are primarily contained in microglial cells. Therefore, it is logical that Aβ exerts its neurotoxic effects (at least partly) through the indirect activation of the KP, the result being the overactivation of KP intermediates with proven destructive capabilities (i.e., 3-HK, ANA, QUIN). Interestingly, in addition to its excitotoxic and ROS-generating effects52, 53, QUIN has recently been demonstrated to activate astrocytes and/or induce astrocytic apoptosis54, 55, as well as stimulate tau hyperphosphorylation in AD possibly through a reduction of tau phosphatases PP2A, PP1, and PP537. This finding provides another potential link between hallmark AD pathologies, specifically Aβ and hyperphosphorylated tau, and the KP.

Perhaps, then, a therapeutic approach aimed at IDO-1 inhibition could prevent the toxic intermediates of the KP from accumulating, thereby partially reducing overall oxidative stress, excitotoxicity, and tau phosphorylation in the brain. While several such inhibitors have been investigated2, none have been analyzed in their capacity to reduce AD stress. Consequently, it may be of therapeutic benefit to study the possibility of IDO-1 inhibition as an AD treatment. Though the inhibition of IDO-1, the upstream rate-limiting enzyme in the KP, may be the most efficacious target for outright prevention of downstream KP intermediates, other KP enzyme inhibitors may be similarly useful for disease modification. A recent study has in fact measured the effect of kynurenine aminotransferase II (KATII) inhibition, the enzyme responsible for the conversion of L-KYN into KYNA (Figure 1).56 These knockout mice, which ultimately express lower levels of KYNA, demonstrated improved cognitive performance, and hippocampal slices from these mice showed significant increases in long-term potentiation. These modifications represent important advances in AD treatment, though they neglect to attenuate the formation of the primary progenitor of oxidative stress in the kynurenine pathway, namely 3-HK.

The finding of significantly lower 3-HK modifications in concomitant AD and DLBD, compared to cases with strictly AD, is quite interesting and opens many additional questions. Notably, the Lewy body variant of AD tends to have significantly lower amounts of NFT pathology than pure AD57. Given our novel finding of the association of IDO with NFTs, perhaps sequestration of IDO-1, a primary KP enzyme (Figure 1), within NFTs interferes with its ability to participate in negative feedback of the expression of KP enzymes; this in turn may lead to an overactivation of the KP and consequent higher level of 3-HK modifications in pure AD. Future studies will focus on revealing the mechanisms behind the observed differences in 3-HK modifications in DLBD type AD and pure AD. As AD is an increasingly burdensome neurodegenerative disease growing in prevalence, any insight into possible therapeutics is of great value. Future research to further elucidate the role of oxidative stress via the KP in AD and other degenerative brain diseases is warranted.

Acknowledgments

This study was supported by the National Institutes of Health [R01 EY016219 (RHN), R01 EY09912 (RHN), P30 EY11373 to the Visual Sciences Research Center of CWRU, and R01 AG026151 (MAS)] and the Alzheimer's Association.

References

1. Beadle GW, Mitchell HK, Nyc JF. Kynurenine as an Intermediate in the Formation of Nicotinic Acid from Tryptophane by Neurospora. Proc Natl Acad Sci U S A. 1947;33:155–158. [PubMed]
2. Takikawa O. Clinical aspects of indoleamine 2,3-dioxygenase (IDO)-initiated tryptophan metabolism: IDO is a target of drug discovery for various diseases. Int Congr Ser. 2007;1304:290–297.
3. Wolf H. Studies on tryptophan metabolism in man. Scand J Clin Lab Invest. 1974;136S:1–186.
4. Dang Y, Dale WE, Brown OR. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med. 2000;28:615–624. [PubMed]
5. Dang Y, Dale WE, Brown OR. Effects of oxygen on kynurenine-3-monooxygenase activity. Redox Rep. 2000;5:81–84. [PubMed]
6. Dale WE, Dang Y, Brown OR. Tryptophan metabolism through the kynurenine pathway in rat brain and liver slices. Free Radic Biol Med. 2000;29:191–198. [PubMed]
7. Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol. 2001;166:6332–6340. [PubMed]
8. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5:2516–2522. [PubMed]
9. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia. 1989;45:535–541. [PubMed]
10. Dang Y, Xia C, Brown OR. Effects of oxygen on 3-hydroxyanthranilate oxidase of the kynurenine pathway. Free Radic Biol Med. 1998;25:1033–1043. [PubMed]
11. Boehm DE, Vincent K, Brown OR. Oxygen and toxicity inhibition of amino acid biosynthesis. Nature. 1976;262:418–420. [PubMed]
12. Braun JS, Sublett JE, Freyer D, et al. Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest. 2002;109:19–27. [PMC free article] [PubMed]
13. Eastman CL, Guilarte TR. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res. 1990;15:1101–1107. [PubMed]
14. Staniszewska MM, Nagaraj RH. 3-hydroxykynurenine-mediated modification of human lens proteins: structure determination of a major modification using a monoclonal antibody. J Biol Chem. 2005;280:22154–22164. [PubMed]
15. Amiridze N, Dang Y, Brown OR. Hydroxyl radicals detected via brain microdialysis in rats breathing air and during hyperbaric oxygen convulsions. Redox Rep. 1999;4:165–170. [PubMed]
16. Dale WE, Dang Y, Amiridze N, Brown OR. Evidence that kynurenine pathway metabolites mediate hyperbaric oxygen-induced convulsions. Toxicol Lett. 2000;117:37–43. [PubMed]
17. Brown OR, Lusiak-Draczynska B. Oxygen inactivation of quinolinate-producing and iron-requiring 3-hydroxyanthranilic acid oxidase: a role in hyperbaric oxygen-induced convulsions? Redox Rep. 1995;1:383–385.
18. Klivenyi P, Toldi J, Vecsei L. Kynurenines in neurodegenerative disorders: therapeutic consideration. Adv Exp Med Biol. 2004;541:169–183. [PubMed]
19. Schwarcz R, Kohler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci Lett. 1983;38:85–90. [PubMed]
20. Schwarcz R, Foster AC, French ED, Whetsell WO, Jr, Kohler C. Excitotoxic models for neurodegenerative disorders. Life Sci. 1984;35:19–32. [PubMed]
21. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981;72:411–412. [PubMed]
22. Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep. 2002;7:199–206. [PubMed]
23. Lim CK, Brew BJ, Guillemin GJ. Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int J Tryptophan Res. 2010;3:1–11. [PMC free article] [PubMed]
24. Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res. 2005;7:103–123. [PubMed]
25. Nemeth H, Toldi J, Vecsei L. Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res. 2005;2:249–260. [PubMed]
26. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol. 2001;64:185–218. [PubMed]
27. Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG. Tryptophan metabolites and brain disorders. Clin Chem Lab Med. 2003;41:852–859. [PubMed]
28. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm. 2000;107:343–353. [PubMed]
29. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol. 2005;31:395–404. [PubMed]
30. Smith MA. Alzheimer disease. Int Rev Neurobiol. 1998;42:1–54. [PubMed]
31. Zhu X, Lee HG, Perry G, Smith MA. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta. 2007;1772:494–502. [PubMed]
32. Kalaria RN. Microglia and Alzheimer's disease. Current Opinion in Hematology. 1999;6:15–24. [PubMed]
33. Shimohama S, Tanino H, Kawakami N, et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun. 2000;273:5–9. [PubMed]
34. Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol. 2003;527:105–112. [PubMed]
35. Guillemin GJ, Kerr SJ, Smythe GA, Armati PJ, Brew BJ. Kynurenine pathway metabolism in human astrocytes. Adv Exp Med Biol. 1999;467:125–131. [PubMed]
36. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78:842–853. [PubMed]
37. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One. 2009;4:e6344. [PMC free article] [PubMed]
38. Takashima A. Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy. J Alzheimers Dis. 2008;14:371–375. [PubMed]
39. Sternberger LA. Immunocytochemistry. Journal. 1986
40. Su B, Wang X, Drew KL, Perry G, Smith MA, Zhu X. Physiological regulation of tau phosphorylation during hibernation. J Neurochem. 2008;105:2098–2108. [PubMed]
41. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000;59:880–888. [PubMed]
42. Lee HG, Ogawa O, Zhu X, et al. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol (Berl) 2004;107:365–371. [PubMed]
43. Smith MA, Zhu X, Tabaton M, et al. Increased Iron and Free Radical Generation in Preclinical Alzheimer Disease and Mild Cognitive Impairment. J Alzheimers Dis. 2009 [PMC free article] [PubMed]
44. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis. 2009;16:763–774. [PMC free article] [PubMed]
45. Zhu X, Su B, Wang X, Smith MA, Perry G. Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci. 2007;64:2202–2210. [PubMed]
46. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:759–767. [PubMed]
47. Kontush A, Berndt C, Weber W, et al. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med. 2001;30:119–128. [PubMed]
48. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998;273:12817–12826. [PubMed]
49. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245–4249. [PubMed]
50. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997;17:2653–2657. [PubMed]
51. Kalaria RN. Microglia and Alzheimer's disease. Curr Opin Hematol. 1999;6:15–24. [PubMed]
52. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77–86. [PubMed]
53. Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, Guillemin GJ. Effects of kynurenine pathway metabolites on intracellular NAD+ synthesis. Int J Tryptophan Res. 2009;2:61–69. [PMC free article] [PubMed]
54. Ting KK, Brew BJ, Guillemin GJ. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation. 2009;6:36. [PMC free article] [PubMed]
55. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation. 2005;2:16. [PMC free article] [PubMed]
56. Potter MC, Elmer GI, Bergeron R, et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010;35:1734–1742. [PMC free article] [PubMed]
57. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. J Neuropathol Exp Neurol. 1993;52:648–654. [PubMed]